9-benzyl-2-chloro-6-(2-furyl)purine profile

9-benzyl-2-chloro-6-(2-furyl)purine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	467621
CHEMBL ID	283137
SCHEMBL ID	1653877
MeSH ID	M0421257

Synonym
9-benzyl-2-chloro-6-(2-furyl)purine
9h-purine, 2-chloro-6-(2-furanyl)-9-(phenylmethyl)-
CHEMBL283137
9-benzyl-2-chloro-6-(furan-2-yl)purine
9-benzyl-2-chloro-6-(2-furanyl)-9h-purine
OBFGIQXNDDQWEJ-UHFFFAOYSA-N
SCHEMBL1653877

Bioassays (37)

Assay ID	Title	Year	Journal	Article
AID144731	Inhibitory activity (at 12.5 ug/mL) against Mycobacterium tuberculosis H37Rv in BACTEC 12B medium using the Microplate Alamar Blue Assay	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	9-Benzylpurines with inhibitory activity against Mycobacterium tuberculosis.
AID247556	Inhibitory concentration against cytotoxicity in VERO cell line	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID104015	Concentration effecting 99% reduction of Mycobacterium tuberculosis strain Erdman, growth in monolayers of mouse bone marrow macrophages after 7 days	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID252942	Selectivity index (IC50:MIC) of the compound	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID1653501	Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by microplate alamar blue assay	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID244936	Minimum inhibitory concentration against Mycobacterium tuberculosis H37Rv	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID103875	Percent inhibition of Mycobacterium tuberculosis H37Rv at 6.25 g/ml concentration in BACTEC 12B medium using microplate alamar blue assay	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID145271	Minimum inhibitory concentration against Mycobacterium tuberculosis H37Rv in BACTEC 12B medium using the Microplate Alamar Blue Assay	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	9-Benzylpurines with inhibitory activity against Mycobacterium tuberculosis.
AID99553	Minimum Inhibitory Concentration against drug-resistant strain of Lactobacillus casei	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID104009	Minimum Inhibitory Concentration against drug-resistant strain resistant to Rifampin	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID455072	Antimicrobial activity against Mycobacterium tuberculosis H37Rv in african green monkey Vero cells by microplate alamar blue assay	2009	Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18	Synthesis, structure, and antimycobacterial activity of 6-[1(3H)-isobenzofuranylidenemethyl]purines and analogs.
AID1653502	Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID235646	Selectivity index was determined by taking ratio of IC50 to that of MIC	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	9-Benzylpurines with inhibitory activity against Mycobacterium tuberculosis.
AID104004	Antibacterial activity against Mycobacterium tuberculosis H37Rv in BACTEC 12B medium using microplate alamar blue assay	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID104006	Minimum Inhibitory Concentration against drug-resistant strain resistant to Ethambutol	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID104014	Concentration effecting 90% reduction of Mycobacterium tuberculosis strain Erdman, growth in monolayers of mouse bone marrow macrophages after 7 days	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID104008	Minimum Inhibitory Concentration against drug-resistant strain resistant to Kanamycin	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID1653590	Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 infected in bone marrow macrophages assessed as reduction in growth after 7 days	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID144865	Antibacterial activity was evaluated against Mycobacterium tuberculosis	2002	Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4	Cytotoxic and antibacterial activity of 2-oxopurine derivatives.
AID244892	Minimum inhibitory concentration against Mycobacterium avium complex	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID103858	Minimum Inhibitory Concentration against drug-resistant strain of Mycobacterium tuberculosis avium	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID104005	Minimum Inhibitory Concentration against drug-resistant strain resistant to Ciprofloxacin	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID1653592	Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as inhibition of [3H]-thymidine incorporation relative to control	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID251735	Tested for the inhibition of Mycobacterium tuberculosis growth at a dose of 12.5 ug/mL	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID740172	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition by radiometric BACTEC assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	6-Oxo and 6-thio purine analogs as antimycobacterial agents.
AID1653503	Selectivity index, ratio of IC50 for African green monkey Vero cells to MIC for antitubercular activity against Mycobacterium tuberculosis H37Rv	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID740174	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 6.25 ug/ml by radiometric BACTEC assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	6-Oxo and 6-thio purine analogs as antimycobacterial agents.
AID217183	Compound was tested for its cytotoxicity in VERO cells (at concentration less than or equal to 62.5 ug/mL or 10 times the MIC for Mycobacterium tuberculosis H37Rv)	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	9-Benzylpurines with inhibitory activity against Mycobacterium tuberculosis.
AID739913	Selectivity index, ratio of CC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv ATCC 27294	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	6-Oxo and 6-thio purine analogs as antimycobacterial agents.
AID246805	Concentration effecting 99% reduction in mycobacterial growth in Mycobacterium tuberculosis affected Macrophage model after 7 days	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID246793	Concentration effecting 90% reduction in mycobacterial growth in Mycobacterium tuberculosis affected Macrophage model after 7 days	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID104016	Minimum Inhibitory Concentration against drug-resistant strain of Mycobacterium tuberculosis Erdman	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID93967	Cytostatic activity against chronic myelogenous leukemia cells (K-562) based on its ability to inhibit [3H]thymidine incorporation.	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID104007	Minimum Inhibitory Concentration against drug-resistant strain resistant to Isoniazid	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
AID251153	Ratio of effective concentration for 90% reduction in mycobacterial growth and minimum inhibitory concentration against Mycobacterium tuberculosis	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID1653499	Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 6.25 ug/ml by microplate alamar blue assay relative to control	2019	Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13	Insights of synthetic analogues of anti-leprosy agents.
AID217186	Minimum inhibitory concentration for testing cytotoxicity in VERO cells	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (71.43)	29.6817
2010's	2 (28.57)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (14.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.	3.31	1	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	3.31	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
clofazimine Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.	3.31	1	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
dapsone [no description available]	3.31	1	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	3.31	1	carbohydrazide	antitubercular agent; drug allergen
nu2058 NU2058: structure in first source	2.08	1
o(6)-benzylguanine O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity	2.08	1
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	3.31	1	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	3.31	1	aminobenzoic acid; phenols	antitubercular agent
pyrimethamine Maloprim: contains above 2 cpds	3.31	1	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	3.31	1	phthalimides; piperidones
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	3.31	1	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	3.31	1	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	3.31	1	kanamycins	bacterial metabolite
acedapsone Acedapsone: Acetylated sulfone that is slowly metabolized to give long-term, low blood levels of DAPSONE. It has antimicrobial and antimalarial action, but is mainly used as a depot leprostatic agent.. acedapsone : A sulfone that is dapsone in which both of the amino groups been acetylation. An antimicrobial drug, it also has antimalarial activity.	3.31	1	acetamides; anilide; secondary carboxamide; sulfone	antimalarial; antimicrobial drug
bis(4-hydroxyphenyl)sulfone bis(4-hydroxyphenyl)sulfone: structure and RN in first source. 4,4'-sulfonyldiphenol : A sulfone that is diphenyl sulfone in which both of the para hydrogens have been replaced by hydroxy groups.	3.31	1	bisphenol; sulfone	endocrine disruptor; metabolite
4,4'-diaminodiphenylmethane 4,4'-diaminodiphenylmethane: RN given refers to parent cpd; structure. 4,4'-diaminodiphenylmethane : An aromatic amine that is diphenylmethane substituted at the 4-position of each benzene ring by an amino group.	3.31	1	aromatic amine	allergen; carcinogenic agent
4,4'-thiodianiline 4,4'-thiodianiline: structure	3.31	1	substituted aniline
monoacetyldapsone monoacetyldapsone: used in leprosy chemotherapy. monoacetyldapsone : A secondary carboxamide resulting from acetylation of one of the amino groups of dapsone.	3.31	1	acetamides; anilide; secondary carboxamide; sulfone
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	3.31	1	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
streptomycin [no description available]	3.31	1	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	3.31	1	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	3.31	1	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
4-amino-4'-hydroxylaminodiphenylsulfone 4-amino-4'-hydroxylaminodiphenylsulfone: RN given refers to unlabeled cpd	3.31	1	sulfonic acid derivative
acediasulfone acediasulfone: antibacterial drug for treatment of ear infections; structure in first source	3.31	1	alpha-amino acid
brodimoprim brodimoprim: inhibits dihydrofolate reductase. brodimoprim : An aminopyrimidine that is 2,4-diaminopyrimidine in which the hydrogen at position 5 has been replaced by a 4-bromo-3,5-dimethoxybenzyl group.	3.31	1	aminopyrimidine; bromobenzenes; methoxybenzenes	antibacterial drug; antiinfective agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
epiroprim epiroprim: an analog of trimethoprim with improved antimicrobial and pharmacokinetic properties; structure given in first source	3.31	1
gentamicin c1a [no description available]	3.31	1	gentamycin C
4-nitro-4'-aminodiphenyl sulfone 4-nitro-4'-aminodiphenyl sulfone: dapsone metabolite; structure given in first source	3.31	1
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	3.31	1	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
methotrexate [no description available]	3.31	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	3.31	1	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
aminopterin Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.	3.31	1	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen
2-methyladenosine 2-methyladenosine : A methyladenosine in which the methyl group is located at position 2 on the adenine ring.	2.45	2	methyladenosine
sitafloxacin [no description available]	3.31	1	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.01	1	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
ethionamide Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.	3.31	1	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
2-chloro-6-(2-furyl)-9-(4-methoxyphenylmethyl)-9h-purine 2-chloro-6-(2-furyl)-9-(4-methoxyphenylmethyl)-9H-purine: has antitubercular activity; structure in first source	2.44	2
cerulenin Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.	3.31	1	epoxide; monocarboxylic acid amide	antifungal agent; antiinfective agent; antilipemic drug; antimetabolite; antimicrobial agent; fatty acid synthesis inhibitor
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	3.82	3	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
thiolactomycin thiolactomycin: from actinomycetes; structure given in first source	3.31	1
rifabutin [no description available]	3.31	1
3'-hydroxy-5'-(4-isobutylpiperazinyl)benzoxazinorifamycin KRM 1648: structure in first source	3.31	1	phenoxazine
krm 1657 KRM 1657: structure given in first source	3.31	1

Condition	Relationship Strength	Studies
Koch's Disease [description not available]	2.47	2
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	2.47	2
Hansen Disease [description not available]	3.12	1
Leprosy A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.	3.12	1

9-benzyl-2-chloro-6-(2-furyl)purine

Description

Cross-References

Synonyms (7)

Bioassays (37)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.75

Study Types

9-benzyl-2-chloro-6-(2-furyl)purine

Description

Cross-References

Synonyms (7)

Bioassays (37)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.75

Study Types

Related Drugs (44)

Related Conditions (4)